The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone

Michael F. Green, Stephen R. Marder, Shirley M. Glynn, Susan R. McGurk, William C. Wirshing, Donna A. Wirshing, Robert P. Liberman, Jim Mintz

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Background: Neurocognitive deficits are core features of schizophrenia that are linked to functional outcome for the disorder. Recent studies and reviews have concluded that newer antipsychotic medications are better for neurocognitive deficits than conventional antipsychotic medications; however, one difficulty in interpreting this literature is that the comparisons have mainly been with high doses of conventional medications. This study examined the neurocognitive effects of low-dose haloperidol compared with risperidone over a 2-year period. Methods: Sixty-two patients were randomly assigned to medication (starting at 6 mg of each medication) and administered neurocognitive batteries six times over the course of follow-up. At 6 months, the mean dose of haloperidol was 5.0 mg, and the mean dose of risperidone was 6.0 mg. Neurocognitive data were reduced into cluster scores and a global summary score. Results: We found no significant overall differences in treatment effects on the cluster scores or the global score. The global score revealed a significant group by time interaction, reflecting the fact that the haloperidol group tended to improve initially and then stay stable, whereas the risperidone group improved more gradually over the follow-up period. Conclusions: This study did not provide support for neurocognitive advantages of a newer antipsychotic medication over a low-dose conventional medication. We speculate that conventional medications may have neurocognitive benefits at low doses that are neutralized or reversed at higher doses.

Original languageEnglish (US)
Pages (from-to)972-978
Number of pages7
JournalBiological Psychiatry
Volume51
Issue number12
DOIs
StatePublished - Jun 15 2002
Externally publishedYes

Fingerprint

Risperidone
Haloperidol
Antipsychotic Agents
Schizophrenia
Therapeutics

Keywords

  • Antipsychotic medications
  • Cognitive deficits
  • Haloperidol
  • Neurocognition
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., ... Mintz, J. (2002). The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone. Biological Psychiatry, 51(12), 972-978. https://doi.org/10.1016/S0006-3223(02)01370-7

The neurocognitive effects of low-dose haloperidol : A two-year comparison with risperidone. / Green, Michael F.; Marder, Stephen R.; Glynn, Shirley M.; McGurk, Susan R.; Wirshing, William C.; Wirshing, Donna A.; Liberman, Robert P.; Mintz, Jim.

In: Biological Psychiatry, Vol. 51, No. 12, 15.06.2002, p. 972-978.

Research output: Contribution to journalArticle

Green, MF, Marder, SR, Glynn, SM, McGurk, SR, Wirshing, WC, Wirshing, DA, Liberman, RP & Mintz, J 2002, 'The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone', Biological Psychiatry, vol. 51, no. 12, pp. 972-978. https://doi.org/10.1016/S0006-3223(02)01370-7
Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA et al. The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone. Biological Psychiatry. 2002 Jun 15;51(12):972-978. https://doi.org/10.1016/S0006-3223(02)01370-7
Green, Michael F. ; Marder, Stephen R. ; Glynn, Shirley M. ; McGurk, Susan R. ; Wirshing, William C. ; Wirshing, Donna A. ; Liberman, Robert P. ; Mintz, Jim. / The neurocognitive effects of low-dose haloperidol : A two-year comparison with risperidone. In: Biological Psychiatry. 2002 ; Vol. 51, No. 12. pp. 972-978.
@article{e048b89578c044c7873bff7d6a1b748c,
title = "The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone",
abstract = "Background: Neurocognitive deficits are core features of schizophrenia that are linked to functional outcome for the disorder. Recent studies and reviews have concluded that newer antipsychotic medications are better for neurocognitive deficits than conventional antipsychotic medications; however, one difficulty in interpreting this literature is that the comparisons have mainly been with high doses of conventional medications. This study examined the neurocognitive effects of low-dose haloperidol compared with risperidone over a 2-year period. Methods: Sixty-two patients were randomly assigned to medication (starting at 6 mg of each medication) and administered neurocognitive batteries six times over the course of follow-up. At 6 months, the mean dose of haloperidol was 5.0 mg, and the mean dose of risperidone was 6.0 mg. Neurocognitive data were reduced into cluster scores and a global summary score. Results: We found no significant overall differences in treatment effects on the cluster scores or the global score. The global score revealed a significant group by time interaction, reflecting the fact that the haloperidol group tended to improve initially and then stay stable, whereas the risperidone group improved more gradually over the follow-up period. Conclusions: This study did not provide support for neurocognitive advantages of a newer antipsychotic medication over a low-dose conventional medication. We speculate that conventional medications may have neurocognitive benefits at low doses that are neutralized or reversed at higher doses.",
keywords = "Antipsychotic medications, Cognitive deficits, Haloperidol, Neurocognition, Risperidone, Schizophrenia",
author = "Green, {Michael F.} and Marder, {Stephen R.} and Glynn, {Shirley M.} and McGurk, {Susan R.} and Wirshing, {William C.} and Wirshing, {Donna A.} and Liberman, {Robert P.} and Jim Mintz",
year = "2002",
month = "6",
day = "15",
doi = "10.1016/S0006-3223(02)01370-7",
language = "English (US)",
volume = "51",
pages = "972--978",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - The neurocognitive effects of low-dose haloperidol

T2 - A two-year comparison with risperidone

AU - Green, Michael F.

AU - Marder, Stephen R.

AU - Glynn, Shirley M.

AU - McGurk, Susan R.

AU - Wirshing, William C.

AU - Wirshing, Donna A.

AU - Liberman, Robert P.

AU - Mintz, Jim

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Background: Neurocognitive deficits are core features of schizophrenia that are linked to functional outcome for the disorder. Recent studies and reviews have concluded that newer antipsychotic medications are better for neurocognitive deficits than conventional antipsychotic medications; however, one difficulty in interpreting this literature is that the comparisons have mainly been with high doses of conventional medications. This study examined the neurocognitive effects of low-dose haloperidol compared with risperidone over a 2-year period. Methods: Sixty-two patients were randomly assigned to medication (starting at 6 mg of each medication) and administered neurocognitive batteries six times over the course of follow-up. At 6 months, the mean dose of haloperidol was 5.0 mg, and the mean dose of risperidone was 6.0 mg. Neurocognitive data were reduced into cluster scores and a global summary score. Results: We found no significant overall differences in treatment effects on the cluster scores or the global score. The global score revealed a significant group by time interaction, reflecting the fact that the haloperidol group tended to improve initially and then stay stable, whereas the risperidone group improved more gradually over the follow-up period. Conclusions: This study did not provide support for neurocognitive advantages of a newer antipsychotic medication over a low-dose conventional medication. We speculate that conventional medications may have neurocognitive benefits at low doses that are neutralized or reversed at higher doses.

AB - Background: Neurocognitive deficits are core features of schizophrenia that are linked to functional outcome for the disorder. Recent studies and reviews have concluded that newer antipsychotic medications are better for neurocognitive deficits than conventional antipsychotic medications; however, one difficulty in interpreting this literature is that the comparisons have mainly been with high doses of conventional medications. This study examined the neurocognitive effects of low-dose haloperidol compared with risperidone over a 2-year period. Methods: Sixty-two patients were randomly assigned to medication (starting at 6 mg of each medication) and administered neurocognitive batteries six times over the course of follow-up. At 6 months, the mean dose of haloperidol was 5.0 mg, and the mean dose of risperidone was 6.0 mg. Neurocognitive data were reduced into cluster scores and a global summary score. Results: We found no significant overall differences in treatment effects on the cluster scores or the global score. The global score revealed a significant group by time interaction, reflecting the fact that the haloperidol group tended to improve initially and then stay stable, whereas the risperidone group improved more gradually over the follow-up period. Conclusions: This study did not provide support for neurocognitive advantages of a newer antipsychotic medication over a low-dose conventional medication. We speculate that conventional medications may have neurocognitive benefits at low doses that are neutralized or reversed at higher doses.

KW - Antipsychotic medications

KW - Cognitive deficits

KW - Haloperidol

KW - Neurocognition

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0037097453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037097453&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(02)01370-7

DO - 10.1016/S0006-3223(02)01370-7

M3 - Article

C2 - 12062881

AN - SCOPUS:0037097453

VL - 51

SP - 972

EP - 978

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 12

ER -